173 related articles for article (PubMed ID: 27910741)
21. Enhanced retention and anti-tumor efficacy of liposomes by changing their cellular uptake and pharmacokinetics behavior.
Li Y; Liu R; Yang J; Shi Y; Ma G; Zhang Z; Zhang X
Biomaterials; 2015 Feb; 41():1-14. PubMed ID: 25522960
[TBL] [Abstract][Full Text] [Related]
22. Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals.
Du J; Lu WL; Ying X; Liu Y; Du P; Tian W; Men Y; Guo J; Zhang Y; Li RJ; Zhou J; Lou JN; Wang JC; Zhang X; Zhang Q
Mol Pharm; 2009; 6(3):905-17. PubMed ID: 19344115
[TBL] [Abstract][Full Text] [Related]
23. Hyaluronic acid-grafted polyamidoamine dendrimers enable long circulation and active tumor targeting simultaneously.
Qi X; Fan Y; He H; Wu Z
Carbohydr Polym; 2015 Aug; 126():231-9. PubMed ID: 25933544
[TBL] [Abstract][Full Text] [Related]
24. An in vitro assessment of liposomal topotecan simulating metronomic chemotherapy in combination with radiation in tumor-endothelial spheroids.
Jyoti A; Fugit KD; Sethi P; McGarry RC; Anderson BD; Upreti M
Sci Rep; 2015 Oct; 5():15236. PubMed ID: 26468877
[TBL] [Abstract][Full Text] [Related]
25. Copper-topotecan complexation mediates drug accumulation into liposomes.
Taggar AS; Alnajim J; Anantha M; Thomas A; Webb M; Ramsay E; Bally MB
J Control Release; 2006 Aug; 114(1):78-88. PubMed ID: 16842880
[TBL] [Abstract][Full Text] [Related]
26. Challenges in development of targeted liposomal therapeutics.
Sawant RR; Torchilin VP
AAPS J; 2012 Jun; 14(2):303-15. PubMed ID: 22415612
[TBL] [Abstract][Full Text] [Related]
27. A novel core-shell lipid nanoparticle for improving oral administration of water soluble chemotherapeutic agents: inhibited intestinal hydrolysis and enhanced lymphatic absorption.
Wang T; Shen L; Zhang Z; Li H; Huang R; Zhang Y; Quan D
Drug Deliv; 2017 Nov; 24(1):1565-1573. PubMed ID: 29029577
[TBL] [Abstract][Full Text] [Related]
28. Stimuli-responsive Smart Liposomes in Cancer Targeting.
Jain A; Jain SK
Curr Drug Targets; 2018 Feb; 19(3):259-270. PubMed ID: 26853324
[TBL] [Abstract][Full Text] [Related]
29. Optimization of vincristine-topotecan combination--paving the way for improved chemotherapy regimens by nanoliposomes.
Zucker D; Barenholz Y
J Control Release; 2010 Sep; 146(3):326-33. PubMed ID: 20685223
[TBL] [Abstract][Full Text] [Related]
30. Repeated injections of PEGylated liposomal topotecan induces accelerated blood clearance phenomenon in rats.
Ma Y; Yang Q; Wang L; Zhou X; Zhao Y; Deng Y
Eur J Pharm Sci; 2012 Apr; 45(5):539-45. PubMed ID: 22155543
[TBL] [Abstract][Full Text] [Related]
31. pH-sensitive liposomes bearing a chemotherapeutic agent and a natural apoptosis modulator for effective intracellular delivery to the solid tumor.
Saraf S; Jain SK
Drug Deliv Transl Res; 2023 Dec; 13(12):2961-2981. PubMed ID: 37306925
[TBL] [Abstract][Full Text] [Related]
32. An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes.
Abraham SA; Edwards K; Karlsson G; Hudon N; Mayer LD; Bally MB
J Control Release; 2004 May; 96(3):449-61. PubMed ID: 15120901
[TBL] [Abstract][Full Text] [Related]
33. Insights into accelerated liposomal release of topotecan in plasma monitored by a non-invasive fluorescence spectroscopic method.
Fugit KD; Jyoti A; Upreti M; Anderson BD
J Control Release; 2015 Jan; 197():10-9. PubMed ID: 25456833
[TBL] [Abstract][Full Text] [Related]
34. Enhancement of the fraction of the active form of an antitumor drug topotecan via an injectable hydrogel.
Chang G; Ci T; Yu L; Ding J
J Control Release; 2011 Nov; 156(1):21-7. PubMed ID: 21777632
[TBL] [Abstract][Full Text] [Related]
35. Nigericin-mediated liposome loading of topotecan: is nigericin a potential drug release regulator?
Cui J; Li C; Wang C; Li Y; Zhang L; Zhang L; Xiu X; Li Y; Wei N
Int J Pharm; 2010 Oct; 399(1-2):31-6. PubMed ID: 20678563
[TBL] [Abstract][Full Text] [Related]
36. Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts.
Némati F; Daniel C; Arvelo F; Legrier ME; Froget B; Livartowski A; Assayag F; Bourgeois Y; Poupon MF; Decaudin D
Anticancer Drugs; 2010 Jan; 21(1):25-32. PubMed ID: 19823076
[TBL] [Abstract][Full Text] [Related]
37. Engineered liposomes bearing camptothecin analogue for tumour targeting:
Saraf S; Jain A; Tiwari A; Verma A; Jain SK
J Liposome Res; 2021 Dec; 31(4):326-341. PubMed ID: 32718195
[TBL] [Abstract][Full Text] [Related]
38. Liposomal encapsulation increases the activity of the topoisomerase I inhibitor topotecan.
Subramanian D; Muller MT
Oncol Res; 1995; 7(9):461-9. PubMed ID: 8835290
[TBL] [Abstract][Full Text] [Related]
39. In-vitro cytotoxicity, in-vivo biodistribution and anti-tumour effect of PEGylated liposomal topotecan.
Hao YL; Deng YJ; Chen Y; Wang KZ; Hao AJ; Zhang Y
J Pharm Pharmacol; 2005 Oct; 57(10):1279-87. PubMed ID: 16259756
[TBL] [Abstract][Full Text] [Related]
40. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
